Craft Health, a Singapore-based health tech startup focusing on deep-tech pharmaceutical drug delivery, has secured a Pre-Series A funding round to advance its 3D printing technology in medicine and supplements.
The funding round was led by Valuence Ventures, backed by other investors, including Mistletoe Singapore, the existing investors, and an angel investor.
Co-founded by Wei Jiang GOH PhD, MBA, and Seng Han LIM PhD in 2019, the startup leverages its innovative 3D printing technology to deliver mass customizations to the compounding pharmacy sector. According to the company’s announcement, reported by VRITIMESSG on Friday, May 30, 2024, the technology could result in unprecedented levels of efficiency and precision.
Since its founding, the startup has developed various automation software, including an end-to-end 3D printing platform to modernize pharmaceuticals and nutraceuticals. This platform integrates cutting-edge solutions such as 3D printing software (CraftControl™), a 3D printer (CraftMake™), and 3D printable formulations (CraftBlends™).
Craft Health has also developed a novel 3D printing database (CraftDatabase™), utilizing semi-solid paste extrusion technology for oral dosage forms. The company’s innovative tech platform can incorporate diverse, active ingredients from small to biological molecules to deliver precise output.
So far, Craft Health’s 3D printing platform has been commercialized for use by nutraceutical start-ups, compounding pharmacies, MNCs, and academics.
Craft Health’s innovative 3D printing technology presents hope for a new era of automation that will increase precision, efficiency, and cost-effectiveness. In turn, this could make personalized medicine more affordable and accessible to patients in need globally.
With the latest investments, Craft Health is looking to advance its technology to commercialization, setting new standards for efficiency and precision in patient-centric care within the pharmaceutical industry.
